In this webinar, you will learn:
- The challenges of developing biologics capable of crossing the blood-brain barrier (BBB) and emerging strategies for engineering BBB-penetrant therapeutics.
- Why multispecifics are an ideal vehicle for delivery of BBB therapeutics.
- How multispecifics targeting the BBB can be designed, validated and optimized for efficient transcytosis and TNF-α targeting capabilities.
- Practical insights into characterizing multispecific antibody protein interactions, including binding orientation, avidity optimization, glycosylation considerations, and other biophysical challenges encountered during development.
- About the evolving landscape of BBB-targeting therapeutics and the future of multispecific delivery platforms.
Engineering Multispecifics for Blood-Brain Barrier Transport
The blood-brain barrier (BBB) remains one of the greatest obstacles in developing biologics for neurological diseases. While advances in antibody engineering have created new opportunities to target the central nervous system, designing molecules that efficiently traverse the BBB, while maintaining therapeutic activity without interfering with the receptor’s intrinsic function, requires careful optimization and comprehensive biophysical characterization.
This webinar will explore the development of NanoNewron’s lead multispecific nanobody therapeutic engineered to cross the BBB through transferrin receptor 1 (TfR1)-mediated transcytosis, highlighting the design, validation, and optimization strategies that guided its development.
Attendees will also gain insight into how SPR was used to narrow candidate molecules and inform the assembly of an optimized multispecific therapeutic for BBB transcytosis. The discussion will cover practical challenges encountered during biophysical characterization, and how they were overcome.
Speaker Bios
Marco Taglietti, MD, PhD
Chief Executive Officer, NanoNewron
Marco Taglietti, MD, Chief Executive Officer. Dr. Taglietti served as President and Chief Executive Officer of Scynexis (Nasdaq:SCYX) from 2015 to 2022, as President of Forest Research Institute and Chief Medical Officer at Forest Laboratories (Nasdaq:FRX) from 2007 until 2014, as Senior Vice President, Head of Global Research at Stiefel Laboratories, from 2004 to 2007 and served in several executive positions from 1992 to 2004 at the Schering-Plough Research Institute. Dr. Taglietti has brought more than 30 different products to market.
Marko Jovic, PhD
Product Manager, SPR
Rapid Novor
Marko leads our Antibody Kinetics team with over 15 years of experience in antibody optimization and development. In his role as a Product Manager, he is using the power of surface plasmon resonance to realize the full potential of antibodies in the development of the next generation of biologics.
Prior to joining Rapid Novor, Marko held leadership roles in biotech, academia, and governmental organizations ranging from the NIH to Nicoya Lifesciences and the Nebraska Medical Center. He has successfully implemented numerous antibody development projects and trained over 100 researchers in the exciting science of SPR.
Marco Taglietti, MD, PhD
Chief Executive Officer, NanoNewron
Marco Taglietti, MD, Chief Executive Officer. Dr. Taglietti served as President and Chief Executive Officer of Scynexis (Nasdaq:SCYX) from 2015 to 2022, as President of Forest Research Institute and Chief Medical Officer at Forest Laboratories (Nasdaq:FRX) from 2007 until 2014, as Senior Vice President, Head of Global Research at Stiefel Laboratories, from 2004 to 2007 and served in several executive positions from 1992 to 2004 at the Schering-Plough Research Institute. Dr. Taglietti has brought more than 30 different products to market.
Marko Jovic, PhD
Senior Sales Executive and Development Manager; Rapid Novor
With a masters in biotechnology and management from the University of Glasgow, Monique has a keen interest in empowering scientists to further their research for better human health. At Rapid Novor, Monique has worked collaboratively with hundreds of scientists in both therapeutic and diagnostic fields globally to understand their goals and apply her proteomics knowledge in tandem with Rapid Novor’s REmAb® service to speed up discovery. When not at a desk or a lab, you can find her globetrotting across Europe and Asia.